靶向药物时代儿童复发/难治性ALK阳性间变性大细胞淋巴瘤的治疗与结局
这项回顾性多机构研究纳入2011至2022年间18家机构收治的81例初诊年龄≤21岁的复发/难治性ALK阳性间变性大细胞淋巴瘤患者,描述靶向药物时代的真实世界治疗与结局。中位复发时间8.9个月,初始再诱导方案包括ALK抑制剂单药(46%)、维布妥昔单抗单药(23%)等,83%达完全缓解;5年无事件生存率63%(95%CI 53-75),5年总生存率91%(95%CI 84-98)。
要点
- 初始再诱导以ALK抑制剂单药(37例,46%)和维布妥昔单抗单药(19例,23%)为主,83%患者达完全缓解。
- 58例接受造血干细胞移植,其中自体11例、异基因48例,1例两者均接受。
- 5年无事件生存率63%(95%CI 53-75),5年总生存率91%(95%CI 84-98)。
核心结论
- 患者对ALK抑制剂或维布妥昔单抗单药再诱导获得良好缓解,但治疗时长和造血干细胞移植的作用仍存疑问。
研究设计与样本
- 回顾性、多机构研究,纳入2011至2022年间18家机构收治的81例初诊年龄≤21岁的复发/难治性ALK阳性间变性大细胞淋巴瘤患者。
主要发现
- 从诊断到复发的中位时间为8.9个月(范围2.6-131.9)。
- 初始再诱导方案为ALK抑制剂单药37例(46%)、维布妥昔单抗单药19例(23%)、不含靶向治疗的化疗12例(15%)、化疗联合靶向治疗9例(11%)、长春碱单药4例(5%),83%的患者对初始再诱导方案达完全缓解。
- 58例接受造血干细胞移植,其中自体11例、异基因48例,1例两者均接受。
- 接受维布妥昔单抗或ALK抑制剂克唑替尼治疗的患者疗程差异很大(维布妥昔单抗1-11年;克唑替尼2-10年)。
- 5年无事件生存率为63%(95%CI 53-75),5年总生存率为91%(95%CI 84-98)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment options for patients with relapsed or refractory (R/R) anaplastic large cell lymphoma (ALCL) have increased in the era of targeted therapies such as brentuximab vedotin (BV) and anaplastic lymphoma kinase (ALK) inhibitors. However, there is no standard treatment and published data evaluating their use are limited. The goal of this retrospective study was to describe current real-world treatment and outcomes of pediatric, adolescent, and young adult patients with R/R ALK-positive ALCL. We conducted a retrospective, multi-institutional study identifying 81 patients with R/R ALK-positive ALCL aged ≤21 years at initial diagnosis treated between 2011 and 2022 across 18 institutions. Median time from diagnosis to relapse was 8.9 months (range, 2.6-131.9). Initial reinduction regimens included ALK-inhibitor monotherapy (n = 37, 46%), BV monotherapy (n = 19, 23%), chemotherapy without targeted therapy (n = 12, 15%), chemotherapy with targeted therapy (n = 9, 11%), or vinblastine monotherapy (n = 4, 5%), with 83% of patients achieving a complete response to initial reinduction regimen. Fifty-eight patients received a hematopoietic stem cell transplant (HSCT), 11 autologous and 48 allogeneic, with 1 receiving both. Duration of treatment for patients receiving BV or the ALK-inhibitor crizotinib (CZ) varied widely (BV, 1-11 years; CZ, 2-10 years). Five-year event-free survival was 63% (95% confidence interval [CI], 53-75) and 5-year overall survival was 91% (95% CI, 84-98). This is, to our knowledge, the largest collection of patients with R/R ALK-positive ALCL treated in the era of targeted therapy. Patients achieved excellent responses to ALK-inhibitor or BV monotherapy, but questions remain about duration of therapy and role of HSCT.
引用
- Marks LJ, Ritter V, Agrusa JE, et al. Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era. Blood Adv. 2025. PMID: 39841960. doi:10.1182/bloodadvances.2024014745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。